Frontiers in Clinical Drug Research - Anti Infectives

Frontiers in Clinical Drug Research - Anti Infectives

Mostrar otras versiones (1)
Detalles Bibliográficos
Autor principal: Atta-ur-Rahman (-)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Sharjah : Bentham Science Publishers 2021.
Colección:EBSCO Academic eBook Collection.
Frontiers in Clinical Drug Research - Anti Infectives.
Acceso en línea:Conectar con la versión electrónica
Ver en Universidad de Navarra:https://innopac.unav.es/record=b47080759*spi
Tabla de Contenidos:
  • Cover
  • Title
  • Copyright
  • End User License Agreement
  • Contents
  • Preface
  • List of Contributors
  • Nucleic Acid and Peptide Aptamers as Potential Antiviral Drugs
  • Serap Evran1,*, Özge Uğurlu1,2, Ezgi Man1, Merve Gültan1 and Canan Özyurt3
  • 1. INTRODUCTION
  • 1.1. The in vitro Selection Methods for Peptide and Nucleic Acid Aptamers
  • 1.2. MRNA Display
  • 1.3. Ribosome Display
  • 1.4. SELEX (Systematic Evolution of Ligands by Exponential Enrichment) for Nucleic Acid Aptamers
  • 1.4.1. Cell-SELEX
  • 1.4.2. Bead-Based SELEX
  • 1.5. Post-SELEX Modifications.
  • 1.6. Modification of Peptide Aptamers for Therapeutic Applications
  • 2. APTAMERS IN VIRAL DIAGNOSIS
  • 2.1. Aptamers in Diagnosis of Hepatitis B Virus (HBV)
  • 2.2. Aptamers in Diagnosis of Hepatitis C Virus (HCV)
  • 2.3. Aptamers in Diagnosis of Human Immunodeficiency Virus (HIV)
  • 2.4. Aptamers in Diagnosis of Influenza
  • 2.5. Aptamers in Diagnosis of Arboviruses
  • 2.6. Aptamers in Diagnosis of SARS Virus
  • 2.7. Aptamers in Diagnosis of Ebola Virus
  • 2.8. Aptamer in Diagnosis of SARS-COV-2
  • 2.9. Aptamers in Diagnosis of Human Papilloma Virus (HPV)
  • 2.10. Aptamer in Diagnosis of Herpes Simplex Virus (HSV)
  • 3. POTENTIALLY THERAPEUTIC APTAMERS AGAINST VIRAL PROTEINS
  • 3.1. Aptamers Against Human Immunodeficiency Virus (HIV) Proteins
  • 3.1.1. Reverse Transcriptase (RT)
  • 3.1.2. Integrase (IN)
  • 3.1.3. Other proteins of HIV-1
  • 3.2. Aptamers Against Hepatitis C Virus (HCV) Proteins
  • 3.2.1. Non-Structural Proteins (NS) of HCV
  • 3.2.2. Structural Proteins of HCV
  • 3.3. Aptamers Against Hepatitis B Virus (HBV) Proteins
  • 3.4. Aptamers Against Severe Acute Respiratory Syndrome (SARS) Coronavirus Proteins.
  • 3.5. Aptamers Against Influenza Virus Proteins
  • 4. CONCLUDING REMARKS
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Host-Directed, Antibiotic-Adjuvant Combination, and Antibiotic-Antibiotic Combination for Treating Multidrug-Resistant (MDR) Gram-Negative Pathogens
  • Wattana Leowattana1,*, Pathomthep Leowattana2 and Tawithep Leowattana3
  • INTRODUCTION
  • MDR GRAM-NEGATIVE PATHOGENS (GNPS)
  • MECHANISM OF RESISTANT DRUGS
  • ESBL-PRODUCING ENTEROBACTERIACEAE
  • CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)
  • MDR A. BAUMANNII
  • HOST-DIRECTED THERAPIES.
  • ANTIBIOTIC-ADJUVANT COMBINATION THERAPY
  • ANTIBIOTIC-ANTIBIOTIC COMBINATION THERAPY
  • TREATMENT OF MDR K. PNEUMONIAE
  • TREATMENT OF MDR P. AERUGINOSA
  • TREATMENT OF MDR A. BAUMANNII
  • TREATMENT OF MDR E. COLI
  • CONCLUDING REMARKS
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Bioactive Substances as Anti-infective Strategies Against Clostridioides Difficile
  • Joana Barbosa1,* and Paula Teixeira1
  • INTRODUCTION
  • PATHOGENESIS AND EPIDEMIOLOGY OF C. DIFFICILE
  • CURRENT APPROACHES IN THE TREATMENT OF CDI
  • Initial Episodes of CDI.

Ejemplares similares